TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status.  Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications. 

TCT 2023 | SWEDEHEART, evolución  a 5 años

The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal) compared T-TEER against medical treatment and did not find differences in mortality or CF related hospitalization at 1 year, but did observe improved health status with T-TEER.

The aim of this prospective, multicenter and randomized study was to assess the benefit of T-TEER in health status. 

Health status was measured by the Kansas questionnaire (KCCQ, Kansas City Cardiomyopathy Questionnaire) based on time reference points: at kickoff, 1 month, 6 months and 1 year. 

Read also: TCT 2023 The LIFE-BTK Trial.

A total 350 patients were randomized: 175 to receiving T-TEER and 175 to medical treatment (MT). Mean age was 78, and most patients were women. At 1 month, T-TEER resulted in improved health status and showed continuous improvement at 1 year, vs. MT. Patients undergoing T-TEER saw better survival and good health status at one year, vs MT patients (74,8% vs. 45,9%, p<0,001) with necessary number to treat (NNT) 3.5.

Conclusion

In conclusion, in this study, patients treated with T-TEER experienced improved health status vs patients receiving MT alone, and this improvement was more evident in patients with symptomatic TR. Improved health status was more evident at 1 month and was maintained at 1 year followup. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Health Status after Transcatheter Tricuspid-Valve Repair in Patients with Severe Tricuspid Regurgitation: Results from the TRILUMINATE Pivotal Trial.

Reference: Suzanne V. Arnold, MD MHA et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....